Phibro Animal Health Corporation PAHC
34.45
0.52
1.53%
as of 25 Sep
- Market cap
- $1.4B
- P/E
- 14.0×
Follow PAHC
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
24.23 | 16.46 | 23.64 | 12.76 |
P/S ratio |
1.17 | 1.03 | 1.50 | 0.84 | |
P/FCF ratio |
47.83 | 32.02 | 175.62 | 129.04 | |
P/Operating CF |
176.31 | 78.25 | 138.40 | 52.84 | |
P/B ratio |
5.26 | 4.56 | 6.20 | 3.30 | |
Price to Tangible BV |
7.56 | 6.32 | 8.30 | 4.31 | |
EV/Sales |
1.64 | 1.48 | 1.93 | 1.27 | |
EV/EBITDA |
11.74 | 9.79 | 12.46 | 7.75 | |
EV/Operating CF |
29.92 | 23.32 | 43.87 | 27.90 | |
EV/FCF |
67.01 | 45.91 | 227.15 | 195.01 | |
Quick Ratio |
1.12 | 1.03 | 1.06 | 1.01 | |
Current Ratio |
3.09 | 3.05 | 3.17 | 2.96 | |
Net Debt/EBITDA |
10.17 | 10.30 | 11.41 | 10.48 | |
Debt/Assets |
53.62% | 52.03% | 50.90% | 48.81% | |
Debt/Equity |
2.38 | 2.20 | 2.03 | 1.90 | |
Asset Turnover |
1.19 | 1.09 | 1.09 | 1.06 | |
Operating CF/Net income |
0.35 | 0.70 | 0.67 | 1.11 | |
Capex/Depreciation |
(1.03) | (0.82) | (1.18) | (1.35) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.83% | 22.02% | 21.12% | 21.74% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.06 | 0.06 | |
Share Based Compensation of Revenue |
0.09% | 0.12% | 0.11% | 0.10% | |
Graham Net Nets |
(0.15) | (0.14) | (0.08) | (0.14) | |
Graham Number |
17.00 | 20.46 | 21.67 | 22.94 | |
Earnings Yield |
4.13% | 6.08% | 4.23% | 7.83% | |
Free Cash Flow Yield |
2.09% | 3.12% | 0.57% | 0.77% | |
Revenue per Share |
8.98 | 9.22 | 9.46 | 9.79 | |
Operating CF per Share |
0.23 | 0.48 | 0.40 | 0.59 | |
Capex per Share |
(0.34) | (0.27) | (0.38) | (0.47) | |
Free Cash Flow per Share |
(0.11) | 0.20 | 0.02 | 0.13 | |
Cash per Share |
2.10 | 1.84 | 1.91 | 2.02 | |
Shareholders Equity per Share |
7.69 | 8.20 | 8.92 | 9.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.69 | 8.20 | 8.92 | 9.51 | |
Free Cash Flow |
(4.50) | 8.26 | 0.89 | 5.23 | |
Working Capital |
565.66 | 579.82 | 612.20 | 619.04 | |
Capital Expenditures |
(13.81) | (11.10) | (15.32) | (18.87) | |
Net Current Asset Value |
(238.04) | (211.01) | (189.22) | (180.26) | |
EV/EBIT |
15.95 | 12.86 | 16.12 | 9.90 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.05 | |
Net Profit Margin |
7.29% | 7.34% | 6.26% | 5.47% | |
Price to Operating Income |
11.39 | 8.97 | 12.46 | 6.55 | |
| Other line items | |||||
Average Receivables |
189.34 | 203.83 | 209.53 | 233.39 | |
Average Payables |
108.56 | 116.37 | 130.63 | 132.76 | |
Average Inventory |
372.17 | 472.29 | 494.04 | 489.65 | |
Average Assets |
1,175.91 | 1,345.53 | 1,381.19 | 1,431.07 | |
Average Common Equity |
285.10 | 289.58 | 313.91 | 335.58 |
Columns are period end dates